We apologize if your country is not currently listed. Please feel free to contact us through our global page and we will do our best to assist you.
Böblingen, February 20, 2025 – The family-owned company Wörwag Pharma achieved an organic revenue growth of 10.5% in 2024, significantly outperforming…
The activity of acute respiratory diseases is at a high level this cold season (1). Accordingly, the risk of infection is high. Often underestimated:…
Bratislava, November 29, 2024 – Wörwag Pharma celebrates its 25th anniversary in the Slovak market this year. CEO Lucia Frzonová looks back on the…
For 25 years, the Wörwag family and the Herrnhuter Missionshilfe e.V. have been committed to education and the fight against poverty in Tanzania. In…
In order to support research and science, Wörwag Pharma announces the 11th Dr. Fritz-Wörwag Research Prize 2024/25.
Böblingen, February 22, 2024 – Wörwag Pharma closed the 2023 financial year with an organic sales growth of 7.6 percent – despite the tense situation…
Böblingen, January 22, 2024 – With the renaming of the most recent investment Mauermann Arzneimittel GmbH & Co. KG, Wörwag Pharma is taking the next…
Böblingen, September 19, 2023 – Wörwag Pharma is taking over contract manufacturer Mauermann-Arzneimittel KG with immediate effect. The…
Böblingen, March 16, 2023 – The Böblingen-based pharmaceutical and family-owned company Wörwag Pharma closed the 2022 financial year with an increase…
Böblingen, February 13, 2023 – The shareholders' meeting of the Wörwag Pharma Group has elected a new Advisory Board: With Konstantin von Alvensleben…